“Pressure is coming from every angle against the pharmaceutical industry, requiring a significant, integrated response,” said Alison Little, KPMG’s advisory life sciences segment leader in the United States. “Life sciences companies face increasingly high demands from payers to prove the value of their products in terms of improved patient outcomes and lower costs.”
The survey respondent also listed the following as having an impact on commercial operations:
• Restrictive regulatory environment: 15 percent
• Shift toward specialty medicines: 12 percent
• Requirements for evidence-based medicine: 9 percent
• Value-based care or decreasing access to healthcare providers: 8 percent
More articles on finance issues:
The Puerto Rican healthcare crisis: 10 things to know
Your only realistic path for reducing revenue gaps
Tenet Q2 profits take $61 million hit, but per-share earnings top estimates
